PALVATA
DEAD

Serial Number

85262092

Owner

BAUSCH HEALTH IRELAND LIMITED

Attorney

Robert J. Gorman

Filing Date

Mar 9, 2011

Add to watchlist:

No watchlists yet
View on USPTO

PALVATA Trademark

Serial Number: 85262092 • Registration: 4647300

PALVATA is a trademark filed by BAUSCH HEALTH IRELAND LIMITED on March 9, 2011. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BAUSCH HEALTH IRELAND LIMITED (240 trademarks)

Dublin 24 , IE

Entity Type: 99

VALEANT PHARMACEUTICALS IRELAND LIMITED (113 trademarks)

3013 LAKE DRIVE
DUBLIN 24 , IE

Entity Type: 99

VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L (72 trademarks)

13-15 AVENUE DE LA LIBERTÉ
LUXEMBOURG CITY 1931 , LU

Entity Type: 99

VALEANT INTERNATIONAL (BARBADOS) SRL (69 trademarks)

WELCHES
CHRIST CHURCH BB17154 , BB

Entity Type: 99

Biovail Laboratories International SRL

Welches
Christ Church BB17154 , BB

Entity Type: 99

Trademark Details

Filing Date

March 9, 2011

Registration Date

December 2, 2014

Published for Opposition

September 16, 2014

Cancellation Date

July 9, 2021

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations and substances for the treatment of skin disorders, diseases, conditions and ailments; pharmaceutical preparations and products for use in dermatology; antifungal preparations; pharmaceutical preparations and substances for the treatment of eye disorders, diseases, conditions and ailments; pharmaceutical preparations and products for ophthalmological use; pharmaceutical preparations and substances for the treatment of disorders, diseases, conditions and ailments of the central nervous system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations and substances for use in chemotherapy; Pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for the treatment of fungal infections, onychomycosis, tinea infections, and similar diseases of the skin and nails; pharmaceutical preparations and substances for use in dermatological conditions

Filing History

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 18, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 11, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 11, 2026 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Apr 16, 2025 ASCK
CANCELLED SEC. 8 (6-YR)
Jul 9, 2021 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 2, 2019 REM1
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jul 10, 2019 ASCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Mar 20, 2019 ASGN
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 16, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 16, 2018 REAP
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 21, 2018 ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 11, 2017 ASGN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 3, 2016 TCCA
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jan 21, 2015 ASCK
REGISTERED-PRINCIPAL REGISTER
Dec 2, 2014 R.PR
PUBLISHED FOR OPPOSITION
Sep 16, 2014 PUBO
NOTICE OF PUBLICATION
Aug 27, 2014 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 8, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 4, 2014 CNSA
FINAL REFUSAL MAILED
Feb 20, 2014 CNFR
FINAL REFUSAL WRITTEN
Feb 19, 2014 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 30, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 29, 2014 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 29, 2014 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 22, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 22, 2014 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 31, 2013 GNRN
NON-FINAL ACTION E-MAILED
Jul 31, 2013 GNRT
NON-FINAL ACTION WRITTEN
Jul 31, 2013 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 11, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 11, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 11, 2013 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 16, 2013 GNRN
NON-FINAL ACTION E-MAILED
Jan 16, 2013 GNRT
NON-FINAL ACTION WRITTEN
Jan 16, 2013 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 7, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 7, 2013 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 7, 2013 ERSI
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Aug 1, 2012 ASCK
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jul 6, 2012 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jul 6, 2012 GNSI
SUSPENSION INQUIRY WRITTEN
Jul 6, 2012 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 3, 2012 RCCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 27, 2012 TEME
ASSIGNED TO LIE
Jun 27, 2012 ALIE
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 26, 2012 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 26, 2012 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 15, 2011 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 15, 2011 GNSL
SUSPENSION LETTER WRITTEN
Dec 15, 2011 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 15, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 15, 2011 CRFA
ASSIGNED TO LIE
Dec 15, 2011 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 9, 2011 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 9, 2011 GNRN
NON-FINAL ACTION E-MAILED
Jun 9, 2011 GNRT
NON-FINAL ACTION WRITTEN
Jun 9, 2011 CNRT
ASSIGNED TO EXAMINER
Jun 9, 2011 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 6, 2011 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 14, 2011 NWOS
NEW APPLICATION ENTERED
Mar 12, 2011 NWAP